Acquisition of Saiba Animal Health AG The recent acquisition of Saiba Animal Health AG expands Boehringer Ingelheim's product portfolio in the pet care industry, presenting an opportunity to introduce new therapeutic medicines for chronic diseases in pets.

Partnership with DHL for warehousing and transport The long-standing partnership with DHL for warehousing and distribution offers potential sales opportunities for logistics and supply chain solutions, especially in the region where Boehringer Ingelheim operates its storage facilities.

Collaboration with Evernorth Care Group Through the partnership with Evernorth Care Group, Boehringer Ingelheim is able to leverage private-label agreements to provide specific products, showcasing potential for tailored pharmaceutical solutions in healthcare settings.

Partnership with CardioHealth Alliance The collaboration with CardioHealth Alliance and other key players presents avenues for marketing Boehringer Ingelheim's products in the realm of chronic kidney disease associated with Type 2 diabetes, tapping into a specialized target market.

Acquisition of Nerio Therapeutics The acquisition of Nerio Therapeutics, with its novel immune checkpoint inhibitors, indicates a strong focus on developing cutting-edge pharmaceutical solutions, signaling potential sales growth through innovative drug offerings.